Ana Maria Jimenez-Garcia

Dr. Ana Maria Jimenez-Garcia

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Open access
AJAna Maria Jimenez-Garcia
Ana Maria Jimenez-Garcia
MVMaria Villarino
Maria Villarino
NANatalia Arias
Natalia Arias
A systematic review and meta‐analysis examined the impact of gut microbiota in Alzheimer's disease (AD) pathogenesis. Dysbiosis may influence neurodegeneration by affecting gut permeability and neurotrophic factors, leading to cognitive decline. The study analyzed microbiome differences between patients with AD and healthy individuals, as well as the impact of various interventions in both preclinical and clinical studies. Of 60 studies reviewed, 12 were excluded from the meta‐analysis due to unsuitable data or lack of control groups. Meta‐analyses revealed significant cognitive impairment in AD patients and animal models, with specific tests identifying these deficits. Notably, Bacteroides levels were higher in patients with AD, whereas probiotics improved Prevotella levels. Natural treatments increased Bacteroidetes and reduced Firmicutes in animal models. The findings emphasize the need for standardized methods to develop therapies targeting the gut microbiota to restore cognition in AD. Understanding individual dysbiosis could further clarify the cognitive effects of the gut–brain axis.Highlights: Dysbiosis in the gut microbiota is linked to cognitive decline in Alzheimer's disease (AD). Patients with AD show significant differences in Bacteroides levels compared to healthy individuals. Probiotic treatments increase Prevotella levels in AD animal models. Natural agents boost Bacteroidetes and reduce Firmicutes in AD animal models. Human studies show no consistent effects of gut microbiota interventions on cognitive function in AD.

29 March 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AJAna Maria Jimenez-Garcia
Ana Maria Jimenez-Garcia
GBGaspard Bonnel
Gaspard Bonnel
AÁAlicia Álvarez-Mota
Alicia Álvarez-Mota
NANatalia Arias
Natalia Arias
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, resulting in muscle weakness, paralysis, and eventually patient mortality. In recent years, neuromodulation techniques have emerged as promising potential therapeutic approaches to slow disease progression and improve the quality of life of ALS patients. A systematic review was conducted until August 8, 2023, to evaluate the neuromodulation methods used and their potential in the treatment of ALS. The search strategy was applied in the Cochrane Central database, incorporating results from other databases such as PubMed, Embase, CTgov, CINAHL, and ICTRP. Following the exclusion of papers that did not fulfil the inclusion criteria, a total of 2090 records were found, leaving a total of 10 studies. R software was used to conduct meta-analyses based on the effect sizes between the experimental and control groups. This revealed differences in muscle stretch measures with manual muscle testing (p = 0.012) and resting motor threshold (p = 0.0457), but not with voluntary isometric contraction (p = 0.1883). The functionality of ALS was also different (p = 0.007), but not the quality of life. Although intracortical facilitation was not seen in motor cortex 1 (M1) (p = 0.1338), short-interval intracortical inhibition of M1 was significant (p = 0.0001). BDNF showed no differences that were statistically significant (p = 0.2297). Neuromodulation-based treatments are proposed as a promising therapeutic approach for ALS that can produce effects on muscle function, spasticity, and intracortical connections through electrical, magnetic, and photonic stimulation. Photobiomodulation stands out as an innovative approach that uses specific wavelengths to influence mitochondria, with the aim of improving mitochondrial function and reducing excitotoxicity. The lack of reliable placebo controls and the variation in stimulation frequency are some of the drawbacks of neuromodulation.

28 July 2023 in Behavior Research Methods
Verified
Journal Article
Open access
PDF file
JWJason Lee Waight
Jason Lee Waight
NANatalia Arias
Natalia Arias
AJAna Maria Jimenez-Garcia
Ana Maria Jimenez-Garcia
MMMatteo Martini
Matteo Martini
Functional near-infrared spectroscopy (fNIRS) relies on near-infrared (NIR) light for changes in tissue oxygenation. For decades, this technique has been used in neuroscience to measure cortical activity. However, recent research suggests that NIR light directed to neural populations can modulate their activity through “photobiomodulation” (PBM). Yet, fNIRS is being used exclusively as a measurement tool. By adopting cognitive tests sensitive to prefrontal functioning, we show that a ‘classical’ fNIRS device, placed in correspondence of the prefrontal cortices of healthy participants, induces faster RTs and better accuracy in some of the indexes considered. A well-matched control group, wearing the same but inactive device, did not show any improvement. Hence, our findings indicate that the ‘standard’ use of fNIRS devices generates PBM impacting cognition. The neuromodulatory power intrinsic in that technique has been so far completely overlooked, and future studies will need to take this into account.

Verified
Journal Article
Open access
PDF file
AJAna Maria Jimenez-Garcia
Ana Maria Jimenez-Garcia
MTMaria Eduarda Tortorella
Maria Eduarda Tortorella
ANAgnes Nishimura
Agnes Nishimura
NANatalia Arias
Natalia Arias
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are linked by shared genetic mutations and overlapping clinical features, forming a clinical spectrum. This systematic review and meta-analysis analysed 97 studies, including 3212 patients with key ALS/FTD gene mutations, to identify gene-specific behavioural profiles. Chromosome 9 open reading frame 72 (C9orf72) mutations were strongly associated with psychotic symptoms and aggression, while superoxide dismutase 1 (SOD1) mutations had minimal cognitive effects. Progranulin (PGRN) mutations correlated with apathy and hallucinations, microtubule-associated protein tau (MAPT) mutations with disinhibition, and charged multivesicular body protein 2B (CHMP2B) with social impairments. Fused in sarcoma (FUS) mutations caused early sleep disturbances, TANK-binding kinase 1 (TBK1) led to disinhibition, and presenilin 1 and 2 (PSEN1/2) was linked to severe aggression. Prodromal cognitive changes in PGRN, MAPT, and CHMP2B mutations suggested early disease onset. Despite overlapping symptoms and clinical heterogeneity, understanding gene-specific patterns could inform tailored care strategies to enhance the quality of life for ALS and FTD patients. This study calls for refined guidelines integrating genetic behavioural profiles to improve patient and family support.

4 April 2025 in Obesity Reviews
Verified
Journal Article
Open access
AJAna Maria Jimenez-Garcia
Ana Maria Jimenez-Garcia
CZCandela Zorzo
Candela Zorzo
AGAlba Gutiérrez‐Menéndez
Alba Gutiérrez‐Menéndez
JAJorge L. Arias
Jorge L. Arias
NANatalia Arias
Natalia Arias
Summary: Introduction: The escalating prevalence of obesity presents a multifaceted challenge involving genetic, environmental, and behavioral factors, with significant public health implications. Photobiomodulation (PBM) may positively influence metabolic activities in adipose cells and regulate inflammation, potentially impacting obesity.Methods: A systematic review and meta‐analysis were conducted to assess the effects of transabdominal PBM treatments in preclinical and clinical obesity studies, covering a range of physical, psychological, and physiological variables. Research articles were sourced from PubMed, Web of Science, ScienceDirect, and Scopus databases. Following the inclusion and exclusion criteria, a total of 24 studies, comprising 1041 patients, and 100 mice were incorporated. R software was employed for conducting meta‐analyses, and calculating effect sizes between experimental and control groups.Results: In human models, significant discrepancies were revealed in waist circumference (Z = ‐2.16; p = 0.031), hip circumference (Z = 2.11; p = 0.035), insulin levels (Z = 2.11; p = 0.035), and triglycerides (Z = ‐2.4674, p = 0.0136). In animal models, significant differences were observed in epididymal adipocyte area (Z = ‐5.6930; p < 0.0001), triglycerides (Z = ‐2.0254; p = 0.04848), and glucose area under the curve (AUC; Z = ‐6.4112; p < 0.0001).Conclusions: This study underscores the necessity of considering diverse wavelengths in PBM research, particularly within the realm of obesity, and emphasizes the imperative for further investigations to comprehensively elucidate PBM mechanisms and applications. The exploration of innovative therapeutic approaches unfolds novel avenues in the pursuit of comprehensive strategies to address obesity and its underlying determinants.

23 February 2022 in Addiction Biology
Verified
Journal Article
Open access
PDF file
LRLeandro Ruiz‐Leyva
Leandro Ruiz‐Leyva
AVAna Vázquez‐Ágredos
Ana Vázquez‐Ágredos
AJAna Maria Jimenez-Garcia
Ana Maria Jimenez-Garcia
OLOlga López-Guarnido
Olga López-Guarnido
APAntonio Pla
Antonio Pla
CCCruz Miguel Cendán
Cruz Miguel Cendán
Animal models of alcohol (ethanol) self‐administration are crucial to dissect the neurobiological mechanisms underlying alcohol dependence, yet only a few of these induce pharmacologically relevant levels of alcohol consumption and rarely the alcohol self‐administration co‐occurs with other addictive behaviours. The present study aims to validate a novel model of voluntary ethanol consumption in male Wistar rats, in which ethanol access follows a binge eating experience. Over 10 sessions, Wistar rats were exposed to binge or control eating (i.e., the ingestion of 11.66 and 0.97 kcal/3 min, respectively, derived from a highly palatable food), immediately followed by two‐bottle choice intake tests (2%, 6%, 10% or 14% w/w ethanol vs. water). Rats exposed to binge eating drank significantly more 6% or 10% (w/w) ethanol than control peers, reaching up to 6.3 gEtOH/kg. Rats stimulated with 2%, 6%, 10% or 14% ethanol after binge eating, but not those given those ethanol concentrations after control eating, exhibited significant within‐group increases in ethanol drinking. This ethanol consumption was not altered by quinine adulteration (up to 0.1 g/L), and it was blocked by naltrexone (10 mg/kg), administered immediately before binge eating. Blood ethanol levels significantly correlated with ethanol consumption; and the more ethanol consumed, the greater the distance travelled in an open field test conducted after the two‐bottle choice test. Altogether, this self‐administration model seems a valid and robust alternative with remarkable potential for research on different stages of the alcohol addiction and, particularly, to assess interactions between alcohol consumption and others addictive‐like behaviours.